fashion -WSS

fashion

author：hotspot 2025-09-28 18:59:40 - browse：32

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

entertainment

knowledge

WSS

What the airline industry can learn from medicine

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Cardiologists urge adding sexual orientation, gender identity to health records

Scientists inch closer to single

Wildfire pollution widens asthma inequities on Long Island

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

knowledge

fashion

hotspot

Peter Hotez and the public health issue of online harassment

5 important ways Henrietta Lacks changed medical science

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Wildfire smoke exposes gaps in outdoor worker protections

The inclusion problem at the heart of rehabilitation research

Psychedelics group wrestles with new pharma identity

TikTok, Instagram influencers need more rules for drug ads

As demand for Covid shots wanes, Moderna seeks its next success

The high personal cost of affirmative action for Black doctors

entertainment

Breakthrough Alzheimer’s drugs are inaccessible in rural states

What the airline industry can learn from medicine

TikTok, Instagram influencers need more rules for drug ads

FDA sets aggressive timeline for overhauling inspection procedures

What the airline industry can learn from medicine

Sage hopes for a blockbuster in antidepressant now before FDA

entertainment

entertainment

knowledge

entertainment